Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2977–3000 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Interventions: TAS0953/HM06; Drug
Lead sponsor: Taiho Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 9
States / cities: Orange, California • Stanford, California • Boston, Massachusetts + 5 more

Conditions: Congenital Hypothyroidism, Hypothyroidism
Interventions: Brand Name Levothyroxine (Synthroid), Generic formulation of Levothyroxine; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Phenylketonurias
Interventions: Show Me FIRST coping skills intervention; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 10 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Hemophilia A, Congenital
Interventions: Alphanate; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: Up to 12 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Atlanta, Georgia • Lexington, Kentucky • Minneapolis, Minnesota + 5 more

Conditions: Bronchopulmonary Dysplasia
Interventions: Minimally invasive surfactant therapy, Continuation on CPAP; Device · Other
Lead sponsor: Menzies Institute for Medical Research; Other
Eligibility: 1 Minute to 6 Hours
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 5
States / cities: New Haven, Connecticut • Honolulu, Hawaii • Evanston, Illinois + 2 more

Conditions: Lynch Syndrome
Interventions: questionnaires, telephone interview, optional blood drawn, questionnaires, telephone interview and optional blood drawn; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2026
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Autosomal Dominant Polycystic Kidney, ADPKD
Interventions: Lixivaptan, Placebo; Drug
Lead sponsor: Palladio Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 23
States / cities: Hoover, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 20 more

Conditions: Sickle Cell Disease
Interventions: VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg, Placebo BID, Placebo TID; Drug
Lead sponsor: Vifor (International) Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: 4-PBA; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cystic Fibrosis
Interventions: Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase); Other
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Phenylketonuria
Interventions: Sapropterin (Kuvan); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Atopic Dermatitis
Interventions: Infrequent versus Frequent Soaking Baths; Behavioral
Lead sponsor: MaineHealth; Other
Eligibility: 6 Months to 11 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Diabetes
Interventions: Gut motility quantification using a capsule after initiating GLP-1RA therapy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Graves' Ophthalmopathy (GO)
Interventions: RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection); Drug · Other
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more

Conditions: Dermatitis, Atopic
Interventions: Mepolizumab 100 mg, Placebo matching mepolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 11
States / cities: Fort Smith, Arkansas • Fremont, California • Santa Ana, California + 8 more

Conditions: Hemophilia A With Inhibitor, Hemophilia A
Interventions: Wilate; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Sacramento, California • San Diego, California • New Orleans, Louisiana

Conditions: Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions: MINI-KID; Other
Lead sponsor: University of South Florida; Other
Eligibility: 6 Years to 17 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
Interventions: linsitinib; Drug
Lead sponsor: Sling Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Miami, Florida • Morgantown, West Virginia

Conditions: Fanconi Anemia
Interventions: microarray analysis, biopsy; Genetic · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Fanconi Anemia, Aplastic Anemia
Interventions: anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 4 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hyperuricemia, Gout
Interventions: ALLN-346, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
Interventions: Olipudase alfa; Drug
Lead sponsor: Sanofi; Industry
Eligibility: Up to 2 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio + 3 more

Conditions: Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Lower Limb Deformity, Post-traumatic Deformity, Complications, Arthroplasty
Interventions: Vanguard XP Bicruciate Knee System, Vanguard CR Knee System; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • Salt Lake City, Utah

Search by objective public record fields.

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Generic vs. Name-Brand Levothyroxine

Development of Novel Psychological Assessment Tools and Anxiety Intervention for Phenylketonuria

Alphanate in Immune Tolerance Induction Therapy

OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP

Multi-Organ Screening Recommendations in Patients With Lynch Syndrome

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

Sapropterin in Individuals With Phenylketonuria

Twice Daily Versus Twice Weekly Soak-and-Seal Baths in Pediatric Atopic Dermatitis

Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

INdividualized ITI Based on Fviii(ATE) Protection by VWF

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System